Teladoc Health
Market Cap
US$5.2b
Last Updated
2019/09/21 00:19 UTC
Data Sources
Company Financials +
Executive Summary
Teladoc Health, Inc. provides virtual healthcare services on a business-to-business in the United States and internationally.
Snowflake
Fundamentals
High growth potential with excellent balance sheet.
Similar Companies
Share Price & News
How has Teladoc Health's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
2.5%
TDOC
2.5%
US Healthcare Services
-0.6%
US Market
1 Year Return
-7.6%
TDOC
10.3%
US Healthcare Services
0.6%
US Market
TDOC underperformed the Healthcare Services industry which returned 8.7% over the past year.
TDOC underperformed the Market in United States of America which returned 1.1% over the past year.
Share holder returns
| TDOC | Industry | Market | |
|---|---|---|---|
| 7 Day | 2.5% | 2.5% | -0.6% |
| 30 Day | 20.7% | -2.9% | 2.2% |
| 90 Day | 13.6% | -4.1% | 1.1% |
| 1 Year | -7.6%-7.6% | 10.4%10.3% | 2.9%0.6% |
| 3 Year | 287.1%287.1% | 51.9%51.6% | 44.6%35.2% |
| 5 Year | n/a | 52.0%51.1% | 61.9%44.2% |
Price Volatility Vs. Market
How volatile is Teladoc Health's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
How Should Investors React To Teladoc Health, Inc.'s (NYSE:TDOC) CEO Pay?3 weeks ago | Simply Wall St
Is Now The Time To Look At Buying Teladoc Health, Inc. (NYSE:TDOC)?1 month ago | Simply Wall St
Estimating The Intrinsic Value Of Teladoc Health, Inc. (NYSE:TDOC)Valuation
Is Teladoc Health undervalued based on future cash flows and its price relative to the stock market?
5.18x
Price to Book (PB) ratio
Intrinsic Value Based on Future Cash Flows
Teladoc Health's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
Teladoc Health's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
Price Based on Earnings
Teladoc Health is loss making, we can't compare its value to the US Healthcare Services industry average.
Teladoc Health is loss making, we can't compare the value of its earnings to the United States of America market.
Price Based on Expected Growth
Unable to calculate PEG ratio for Teladoc Health, we can't assess if its growth is good value.
Price Based on Value of Assets
Teladoc Health is overvalued based on assets compared to the US Healthcare Services industry average.
Next Steps
Future Growth
How is Teladoc Health expected to perform in the next 1 to 3 years based on estimates from 20 analysts?
55.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Estimates
Future Annual Growth Analysis
Teladoc Health's revenue is expected to grow significantly at over 20% yearly.
Teladoc Health's earnings are expected to grow significantly at over 20% yearly.
Teladoc Health's revenue growth is expected to exceed the United States of America market average.
Teladoc Health's earnings growth is expected to exceed the United States of America market average.
Teladoc Health's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Earnings per Share Growth Estimates
Future Return on Equity
Teladoc Health is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
Next Steps
Past Performance
How has Teladoc Health performed over the past 5 years?
-26.0%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Teladoc Health does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
Unable to compare Teladoc Health's 1-year earnings growth to the 5-year average as it is not currently profitable.
Unable to compare Teladoc Health's 1-year growth to the US Healthcare Services industry average as it is not currently profitable.
Return on Equity
It is difficult to establish if Teladoc Health has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
Return on Assets
It is difficult to establish if Teladoc Health has efficiently used its assets last year compared to the US Healthcare Services industry average (Return on Assets) as it is loss-making.
Return on Capital Employed
It is difficult to establish if Teladoc Health improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Next Steps
Financial Health
How is Teladoc Health's financial position?
Financial Position Analysis
Teladoc Health is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Teladoc Health's cash and other short term assets cover its long term commitments.
Debt to Equity History and Analysis
Teladoc Health's level of debt (42.6%) compared to net worth is high (greater than 40%).
The level of debt compared to net worth has been reduced over the past 5 years (43.3% vs 42.6% today).
Balance Sheet
Low level of unsold assets.
Debt is covered by short term assets, assets are 1.2x debt.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Whilst loss making Teladoc Health has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.
Whilst loss making Teladoc Health has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by -53.5% per year.
Next Steps
Dividend
What is Teladoc Health's current dividend yield, its reliability and sustainability?
Dividend Yield and Payments Analysis
Unable to evaluate Teladoc Health's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Teladoc Health's dividend against the top 25% market benchmark as the company has not reported any payouts.
Unable to perform a dividend volatility check as Teladoc Health has not reported any payouts.
Unable to verify if Teladoc Health's dividend has been increasing as the company has not reported any payouts.
Current Payout to Shareholders
Unable to calculate sustainability of dividends as Teladoc Health has not reported any payouts.
Future Payout to Shareholders
No need to calculate the sustainability of Teladoc Health's dividends in 3 years as they are not expected to pay a notable one for United States of America.
Next Steps
Management
What is the CEO of Teladoc Health's salary, the management and board of directors tenure and is there insider trading?
4.0yrs
Average management tenure
CEO
Jason Gorevic (47yo)
10.3yrs
Tenure
US$7,329,322
Compensation
Mr. Jason N. Gorevic has been Chief Executive Officer at TelaDoc, Inc. (Formerly TelaDoc Medical Services Inc.) since June 2009. Mr. Gorevic serves as Director of Doximity, Inc. since April 2019. Mr. Gorev ...
CEO Compensation Analysis
Jason's remuneration is about average for companies of similar size in United States of America.
Jason's compensation has increased whilst company is loss making.
Management Age and Tenure
4.0yrs
Average Tenure
50yo
Average Age
The tenure for the Teladoc Health management team is about average.
Board Age and Tenure
4.7yrs
Average Tenure
65.5yo
Average Age
The tenure for the Teladoc Health board of directors is about average.
Insider Trading
No 3 month open market individual insider trading information.
Recent Insider Transactions
| Entity | Individual |
| Shares | 1,188 |
| Max Price | US$60.00 |
Ownership Breakdown
Management Team
Jason Gorevic (47yo)
CEO & Director
- Tenure: 10.3yrs
- Compensation: US$7.33m
Peter McClennen (50yo)
President
- Tenure: 1.8yrs
- Compensation: US$4.89m
George Brooks
Co-Founder
- Tenure: 17.7yrs
Jeff Nadler (55yo)
Chief Information Officer
- Tenure: 0yrs
Adam Vandervoort (44yo)
Chief Legal Officer & Secretary
- Tenure: 4.6yrs
- Compensation: US$1.99m
Gabriel Cappucci (56yo)
Chief Accounting Officer
- Tenure: 4.3yrs
David Sides (48yo)
Chief Operating Officer
- Tenure: 0.2yrs
Stephany Verstraete (50yo)
Chief Marketing Officer
- Tenure: 3.7yrs
- Compensation: US$1.73m
Kelsey Turcotte
Vice President of Investor Relations
- Tenure: 0yrs
Mala Murthy (55yo)
Chief Financial Officer
- Tenure: 0.3yrs
Board Members
Tom McKinley (67yo)
Independent Director
- Tenure: 9.8yrs
- Compensation: US$246.17k
Arneek Multani (45yo)
Independent Director
- Tenure: 11.7yrs
- Compensation: US$248.67k
David Shedlarz (71yo)
Director
- Tenure: 3yrs
- Compensation: US$258.67k
Michael Goldstein (77yo)
Independent Director
- Tenure: 4.6yrs
- Compensation: US$252.50k
David Snow (64yo)
Chairman
- Tenure: 4.8yrs
- Compensation: US$274.34k
Bill Frist (67yo)
Independent Director
- Tenure: 5yrs
- Compensation: US$245.17k
Jason Gorevic (47yo)
CEO & Director
- Tenure: 10.3yrs
- Compensation: US$7.33m
Ken Paulus (59yo)
Director
- Tenure: 2.6yrs
- Compensation: US$240.17k
Brian McAndrews (60yo)
Director
- Tenure: 2yrs
- Compensation: US$248.67k
Helen Darling (77yo)
Director
- Tenure: 3.3yrs
- Compensation: US$236.17k
Company Information
Teladoc Health, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Teladoc Health, Inc.
- Ticker: TDOC
- Exchange: NYSE
- Founded: 2002
- Industry: Health Care Technology
- Sector: Healthcare
- Market Cap: US$5.198b
- Shares outstanding: 72.04m
- Website: https://www.teladochealth.com
Number of Employees
Location
- Teladoc Health, Inc.
- 2 Manhattanville Road
- Suite 203
- Purchase
- New York
- 10577
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| TDOC | NYSE (New York Stock Exchange) | Yes | Common Stock | US | USD | Jul 2015 |
| 4LL | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jul 2015 |
| 0LDR | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | Jul 2015 |
Biography
Teladoc Health, Inc. provides virtual healthcare services on a business-to-business in the United States and internationally. It covers various clinical conditions, including non-critical, episodic care, c ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/09/21 00:19 |
| End of Day Share Price | 2019/09/20 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.